期刊
EXPERIMENTAL AND THERAPEUTIC MEDICINE
卷 26, 期 3, 页码 -出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2023.12115
关键词
melanoma; targeted therapy; immunotherapy; combination therapy
Melanoma, the most aggressive and deadly type of skin cancer, has a poor prognosis with metastasis. Recently, new and effective therapies, including targeted agents and immunotherapy, have emerged for metastatic melanoma. This article reviews recent clinical trials of targeted therapy and immunotherapy for metastatic melanoma, with a focus on improving treatment efficacy.
Melanoma is the most aggressive and deadly type of skin cancer and is known for its poor prognosis as soon as metastasis occurs. Since 2011, new and effective therapies for metastatic melanoma have emerged, with US Food and Drug Administration approval of multiple targeted agents, such as V-Raf murine sarcoma viral oncogene homolog B1/mitogen-activated protein kinase kinase inhibitors and multiple immunotherapy agents, such as cytotoxic T lymphocyte-associated protein 4 and anti-programmed cell death protein 1/ligand 1 blockade. Based on insight into the respective advantages of the above two strategies, the present article provided a review of clinical trials of the application of targeted therapy and immunotherapy, as well as novel approaches of their combinations for the treatment of metastatic melanoma in recent years, with a focus on upcoming initiatives to improve the efficacy of these treatment approaches for metastatic melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据